在癌症基因治疗中使用NF-κB激活的基因抑制策略
Wei Dai1, Jian Wu2, Yingchun Shui3
1School of Animal Science and Food Engineering, Jinling Institute of Technology, Nanjing, 210038, China.
Cancer gene therapy
|September 3, 2024
概括
这项研究引入了HOPE,一种新型基因治疗,激活CRISPR-Cas13a以抑制TERT和MYC等癌症驱动基因. HOPE有效地在体外和体内消除癌细胞,为癌症治疗提供了一个有前途的新途径,副作用最小.
科学领域:
- 在瘤学瘤学.
- 基因治疗 基因治疗
- 分子生物学分子生物学
背景情况:
- 核因子-kappa B (NF-κB) 在大多数癌症中过度活跃,使其成为治疗点.
- 现有的NF-κB抑制剂通常会引起副作用,限制临床成功.
- 需要一种新的方法来有效地准癌症,同时尽量减少毒性.
研究的目的:
- 开发和评估一种新的基因治疗方法,希望,用于癌症治疗.
- 利用NF-κB活性激活CRISPR-Cas13a以进行向性瘤基因抑制.
- 在临床前癌症模型中评估HOPE的疗效和安全性.
主要方法:
- 使用NF-κB特异性促进剂 (DMP) 构建了一个系统 (HOPE),以激活CRISPR-Cas13a.
- 在mRNA层面上,HOPE针对和抑制瘤基因 (TERT,PLK1,KRAS,MYC).
- 在细胞培养和使用腺相关病毒 (AAV) 输送的结直肠癌小鼠模型中评估了HOPE的抗瘤作用.
主要成果:
- 在没有伤害正常细胞的情况下,HOPE在体外选择性诱导癌细胞死亡.
- 静脉注射RAAV-HOPE显著抑制了小鼠的瘤生长.
- 希望治疗激活了免疫系统,并减少了癌细胞干细胞.
- 在体内模型中没有观察到任何显著的副作用.
结论:
- 希望在体外和体内都显示出强大的抗瘤活性.
- 这种新型基因治疗方法为癌症治疗提供了一个有希望的策略.
- 通过向瘤基因和调节免疫反应,HOPE代表了癌症基因治疗的潜在进步.
相关概念视频
NF-κB-dependent Signaling Pathway
7.4K
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
NF-κB-dependent Signaling Mechanism
The...
7.4K
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Cancer-Critical Genes I: Proto-oncogenes
8.7K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
8.7K
Cancer-Critical Genes II: Tumor Suppressor Genes
7.3K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
7.3K
Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K


